The US Food and Drug Administration plans by 3 April to suspend all domestic good manufacturing practice surveillance and non-critical for-cause and pre-approval inspections for the duration of the novel coronavirus public health crisis as part of decision to require all eligible employees to work remotely
Exceptions will be made for inspections of facilities manufacturing medically necessary products, such as products to treat and prevent Covid-19, the disease caused by the